Transcription of listed. - CINVANTI™ (aprepitant) injectable emulsion
{{id}} {{{paragraph}}}
Example: tourism industry
listed. - CINVANTI™ (aprepitant) injectable emulsion
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CINVANTITM safely and effectively. See full prescribing information for CINVANTI. CINVANTITM ( aprepitant) injectable emulsion , for intravenous use Initial Approval: 2003 ----------------------------INDICATIONS AND USAGE---------------------------- CINVANTI is a substance P/neurokinin-1 (NK 1) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of: acute and delayed nausea and vomiting associated with initial and repeatcourses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. (1) nausea and vomiting associated with initial and repeat courses ofmoderately emetogenic cancer chemotherapy (MEC).
5 . 5 WARNINGS AND PRECAUTIONS 5.1 Clinically Significant CYP3A4 Drug Interactions Aprepitant is a substrate, weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4.
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
Lecture 6 Emulsion technology, Lecture 6 - Emulsion technology, Emulsio n, Emulsion, Course "ADVANCES IN EMULSION POLYMERIZATION AND LATEX TECHNOLOGY, Krystal 25 Emulsion EF, Polydimethylsiloxane antifoam emulsion, Emulsion Spray, ZEALAND DATA SHEET 1. PRODUCT NAME, ZEALAND DATA SHEET. 1. PRODUCT NAME